Health Canada has granted聽聽for Amylyx 色界吧s鈥� Albrioza (sodium phenylbutyrate and ursodoxicoltaurine, AMX0035), with conditions, to treat .听
An oral fixed-dose combination therapy, Albrioza is claimed to lower neuronal cell death, hypothesised to happen by mitigating endoplasmic reticulum (ER) stress and mitochondrial dysfunction at the same time.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The latest development marks the first marketing approval for Albrioza.
According to clinical findings, ALS patients who received Albrioza, either as a stand-alone treatment or along with current ALS therapies, had a statistically significant and clinically meaningful benefit in functional outcomes versus placebo.
The regulatory agency authorised the approval of Albrioza under the Notice of Compliance with Conditions policy.
One of the approval conditions is the submission of findings from the ongoing placebo-controlled, randomised Phase III PHOENIX trial of AMX0035 while further or ongoing studies are included as other conditions.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTopline results from the PHOENIX trial are anticipated in 2024.
The latest approval is based on findings from a multicentre Phase II CENTAUR clinical trial that enrolled 137 ALS patients.
The trial had a six-month, randomised placebo-controlled phase and an open-label long-term follow-up phase.
Data showed that Albrioza-treated subjects scored, on average, 2.32 points better on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) over a 24-week duration.
Amylyx 色界吧s Canada general manager and head Chris Aiello said: 鈥淲e anticipate that Albrioza will be available commercially in Canada within the next six weeks.
鈥淲e are prepared to work with the pan-Canadian 色界吧 Alliance (pCPA) and federal, provincial and territorial governments to negotiate the listing of Albrioza expeditiously so that eligible Canadians living with ALS can obtain access as quickly and efficiently as possible.鈥�
